Navigation Links
Helix BioPharma Announces Q1 2009 Financial Results
Date:12/11/2008

for gross proceeds of $11,424,000. Each unit consists of one common share and one-half common share purchase warrant with each whole common share purchase warrant entitling the holder to purchase, subject to adjustment, one common share at a price of $2.36 until 5pm (Toronto time) on October 1, 2011.

The total number of common shares issued as at October 31, 2008 was 53,175,335 (July 31, 2008 - 46,375,335).

At October 31, 2008, the Company's working capital was $26,534,000 (July 31, 2008 - $19,166,000).

Based on our planned expenditures and assuming no material unanticipated expenses, we believe that our cash reserves and expected cash from operations will be sufficient to meet our anticipated cash needs for working capital and capital expenditures for the next twelve months.

The Company will continue to seek additional funding, primarily by way of equity offerings, to carry out its business plan and to minimize risks to its operations. The market, however, for equity financings for companies such as Helix is challenging, and there can be no assurance that additional funding by way of equity financing will be available. The failure of the Company to obtain additional funding on a timely basis may result in the Company reducing, delaying or cancelling one or more of its planned research, development and marketing programs and reducing related personnel, any of which could impair the current and future value of the business. Any additional equity financing, if secured, may result in significant dilution to the existing shareholders at the time of such financing. The Company may also seek additional funding from other sources, including technology licensing, co-development collaborations, and other strategic alliances, which, if obtained, may reduce the Company's interest in its projects or products. There can be no assurance, however, that any alternative sources of funding will be availab
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014 /PRNewswire/ ... company focused on gynecologic disease, announced today that ... with investors including Oracle Investment Management, Jack ... Vermillion directors. Total proceeds were $10.5 million, before ... working capital and general corporate purposes. ...
(Date:12/24/2014)... December 23, 2014 Earlier this year ... L. Sherley, director of the Adult Stem Cell Technology ... often overlooked and under appreciated unique property of adult ... Distributed Stem Cells: Misunderstood in the Past, Important for ... congress participants. He gave the address at the ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 ... mercaptan such as its definition, classification, application ... product specification, manufacturing process, and product cost ... and applications. The analysis also covers upstream ... channels, industry development trend and proposals. In ...
(Date:12/24/2014)... , Dec. 23, 2014 China ... the "Company"), a leading fully integrated plasma-based biopharmaceutical ... announced that its majority-owned subsidiary, Shandong Taibang Biological ... ("GMP") certification from the China Food and Drug ... production facility. As previously disclosed in the Company,s ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3
... LASIK Eye Surgeons directory service and information resource ... the Trusted LASIK Surgeons directory apart is a ... LASIK Surgeons in the United States are listed. ... R. Wayne Bowman, are screened based on their ...
... is to determine whether therapy after childbirth for women with ... Willebrand disease is needed and for how ... Behring is providing,a $1.2 million grant to fund a first-of-its ... for determining optimal prophylaxis,treatment for postpartum women with von Willebrand ...
... Mass., Aug. 18 Logical Therapeutics, Inc., ... medicines that treat,diseases associated with poorly controlled ... Phase 1b randomized controlled multi-dose,safety and pharmacokinetics ... The study, which was conducted from December, ...
Cached Biology Technology:Trusted LASIK Surgeons Welcomes Dallas LASIK Eye Surgery Specialist Dr. R. Wayne Bowman to its LASIK Directory 2Trusted LASIK Surgeons Welcomes Dallas LASIK Eye Surgery Specialist Dr. R. Wayne Bowman to its LASIK Directory 3Trusted LASIK Surgeons Welcomes Dallas LASIK Eye Surgery Specialist Dr. R. Wayne Bowman to its LASIK Directory 4Trusted LASIK Surgeons Welcomes Dallas LASIK Eye Surgery Specialist Dr. R. Wayne Bowman to its LASIK Directory 5Trusted LASIK Surgeons Welcomes Dallas LASIK Eye Surgery Specialist Dr. R. Wayne Bowman to its LASIK Directory 6Video: CSL Behring Provides $1.2M Grant for World's First Study of Postpartum Women with VWD, Common Bleeding Disorder 2Video: CSL Behring Provides $1.2M Grant for World's First Study of Postpartum Women with VWD, Common Bleeding Disorder 3Video: CSL Behring Provides $1.2M Grant for World's First Study of Postpartum Women with VWD, Common Bleeding Disorder 4Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug 2
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally ... more evident than at international borders. Over the ... scanners have allowed veteran travelers to self process ... Control (APC) Kiosks at an increasing number of ... According to Maxine Most ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has ... in India 2015-2019" report to their offering. ... this market is the adoption of multimodal biometric ... characteristic of an individual for verification and identification ...
(Date:12/10/2014)... NEW YORK , Dec. 8, 2014 You,ve ... online banking account but can,t remember your password, site key ... birthday? Who was your first grade teacher? ... launches the app that will finally put an ... PINs – 1U TM . 1U leverages a ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... that Western University scientists call "Forrest Gump" because, like ... aren,t smart, is furthering the understanding of a key ... team at Robarts Research Institute say the mice show ... available in the brain. Boosting ACh is a ...
... Calif. , June 20, 2013 Based on ... & Sullivan recognizes geneOnyx Limited with the 2013 European ... leverages a DNA testing platform originally used for medical ... anti-aging cosmetics. geneOnyx,s test requires only a ...
... of the patients who received injections of steroids contaminated ... Compounding Center has found that some patients had fungal ... of their symptoms and that magnetic resonance imaging (MRI) ... received injections from highly contaminated lots. The ...
Cached Biology News:'Forrest Gump' mice show too much of a good thing, can be bad 2Frost & Sullivan Applauds geneOnyx for its DNA Testing Solution for the Personalized Cosmeceuticals Market 2Frost & Sullivan Applauds geneOnyx for its DNA Testing Solution for the Personalized Cosmeceuticals Market 3Frost & Sullivan Applauds geneOnyx for its DNA Testing Solution for the Personalized Cosmeceuticals Market 4Evolution of an outbreak: Complications from contaminated steroid injections 2
Request Info...
... coated microplates can be used for efficient, ... fusion proteins for ELISA or other assays ... such proteins are bound with high efficiency ... left) and will not elute during the ...
... Direct SPA Screening Assay, 5 ... that eliminate lengthy sample extraction procedures ... use).Range: 1.32-84.28 ng/ml (4-256 pmol/ml).Sensitivity: 0.65 ... 2-8 C. Category: Drug Screening & ...
...
Biology Products: